Cizzle Biotechnology Holdings PLC Final results for the year ended 31 December 2023

RNS Number : 5816M

Cizzle Biotechnology Holdings PLC

30 April 2024

 

30 April 2024

Cizzle Biotechnology Holdings plc

 

("Cizzle", "Cizzle Biotechnology", or the "Company")

 

Final results for the year ended 31 December 2023

 

Cizzle Biotechnology, the UK based diagnostics developer, announces the publication of the Company's Annual Report and Financial Statements for the year ended 31 December 2023.

The Annual Financial Report is available via http://www.rns-pdf.londonstockexchange.com/rns/5816M_1-2024-4-30.pdf and will shortly be available to view on the Company's website at: https://cizzlebiotechnology.com

 

Enquiries:

 

Cizzle Biotechnology Holdings plc	Via IFC Advisory
Allan Syms (Executive Chairman)

 

Allenby Capital Limited - Joint Broker and Financial Adviser		[phone]
John Depasquale
George Payne

 

Novum Securities Limited - Joint Broker	[phone]
Colin Rowbury Jon Bellis

 

IFC Advisory Limited - Financial Public Relations	[phone]
Tim Metcalfe
Florence Chandler

 

About Cizzle Biotechnology

Cizzle is developing a blood test for the early detection of lung cancer. The Company is a spin- out from the University of York, founded in 2006, around the work of Professor Coverley and colleagues. Its proof-of-concept prototype test is based on the ability to detect a stable plasma biomarker, a variant of CIZ1 known as CIZ1B. CIZ1 is a naturally occurring cell nuclear protein involved in DNA replication, and the targeted CIZ1B variant is highly correlated with early-stage lung cancer. For more information, please see https://cizzlebiotechnology.com

You can also follow the Company through its twitter account @CizzlePlc and on LinkedIn

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

DOCEAPLEDENLEEA